CYTK Form 4: CEO Robert Blum Sells 5,000 Shares at $55.05

Robert I. Blum, President & CEO and Director of Cytokinetics, reported a sale of common stock on 10/01/2025.

Rhea-AI Filing Summary

Robert I. Blum, President & CEO and Director of Cytokinetics, reported a sale of common stock on 10/01/2025. The Form 4 shows 5,000 shares were disposed of at a price of $55.05. After the reported sale, the filing lists 368,108 shares held directly and 2,083 shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust. The form was signed by an attorney-in-fact on behalf of Mr. Blum.

Insights

Financial Analyst

TL;DR: Insider sale of 5,000 shares is a routine disposition that modestly reduces direct holdings but does not materially change ownership stake.

The Form 4 documents a single non-derivative sale of 5,000 Cytokinetics (CYTK) shares at $55.05 on 10/01/2025 by Robert I. Blum, who serves as President & CEO and a director. The filing reports 368,108 shares held directly and two trusts each holding 2,083 shares indirectly. This is a straightforward Section 16 disclosure of a trade; the absolute size (5,000 shares) is small relative to the reported direct holding. No derivative transactions, option exercises, or new grants are reported. From an analyst perspective, this is a routine liquidity event by an insider without additional context in the filing to indicate a change in control or strategy.

Corporate Governance Expert

TL;DR: The disclosure complies with Section 16 reporting requirements and shows an attorney-in-fact signature; no governance red flags appear in this filing.

The Form 4 identifies Mr. Blums roles as both an officer and director and records a sale of 5,000 shares at $55.05. The filing includes clear beneficial ownership breakdowns: direct ownership of 368,108 shares and indirect holdings via two named irrevocable trusts of 2,083 shares each. The form is executed by an attorney-in-fact, which is an acceptable practice when properly authorized. There are no indications of unexplained transfers, accelerations, or related-party transactions in this submission.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 5,000 shs ($275K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$55.05	$275K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 368,108 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1); Common Stock — 2,083 shares (Indirect, by Trust 2)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Robert I. Blum report on the Form 4 for CYTK?

The Form 4 reports a sale of 5,000 common shares on 10/01/2025 at a price of $55.05 per share.

How many Cytokinetics (CYTK) shares does Robert I. Blum own after the reported transaction?

The filing lists 368,108 shares held directly and 2,083 shares in each of two trusts as indirect holdings.

What indirect holdings are disclosed for Mr. Blum on this Form 4?

Indirect holdings are shown as 2,083 shares by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

Who signed the Form 4 on behalf of the reporting person?

The form was signed by John O. Faurescu, attorney-in-fact for Mr. Blum on 10/01/2025.

Does the Form 4 report any derivative transactions or option activity for Mr. Blum?

No. Table II (derivative securities) contains no reported transactions; only a non-derivative common stock sale is shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/01/2025 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S		5,000	D	$55.05	368,108	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.